Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
453.70    -5.90 (-1.28%)
Bid:
454.70
Ask:
454.90
Spread: 0.20 (0.044%)
Market Cap: £5.65b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

Trading Statement

5 May 2022 07:00

RNS Number : 3655K
Melrose Industries PLC
05 May 2022
 

 

 

 

 

 

5 May 2022

 

 

 

MELROSE INDUSTRIES PLC

 

AGM Trading Statement

 

Melrose Industries PLC ("Melrose" or the "Group") publishes the following trading update for the four months from 1 January to 30 April 2022 (the "Period") ahead of its Annual General Meeting taking place later today.

 

Group trading

 

Trading is in line with expectations for the year. Consistent with industry trends, the Aerospace division is experiencing continued growth with with like-for-like sales up 6% and the Automotive and Powder Metallurgy divisions remaining constrained by supply, with combined like-for-like sales down 4%, significantly below underlying consumer demand levels.

 

The Melrose Board is confident that the well advanced restructuring actions ensure all its businesses are positioned to deliver their full potential as supply constraints ease. In addition substantial progress has been made in recovering inflation. Due to the time lag effect the financial performance will be second half weighted, but Melrose is confident the impact of inflation can be offset by the measures taken.

 

Investor Day

 

Melrose will be holding an Investor Day on GKN Aerospace on 8 June, starting at 2.30pm, to explain in more detail the full potential for the business including growth and improvement opportunities, excellent long-term cash flow dynamics and new sustainable technology.

 

 

Simon Peckham, CEO of Melrose Industries PLC, said:

 

"Your Group continues to make good progress whilst dealing with the broader world challenges. We are increasingly seeing growth return to our Aerospace business, which is being rapidly well positioned for its future, and are confident of demonstrating the full quality of our largely restructured automotive businesses. We are well set to realise shareholder value as conditions improve."

 

-ends-

 

Enquiries:

Montfort Communications: Nick Miles

+44 (0) 20 3514 0897 / +44 (0) 7739 701 634

miles@montfort.london

 

Charlotte McMullen

+44 (0) 20 3514 0897 / +44 (0) 7921 881 800

mcmullen@montfort.london

 

Melrose Investor Relations: Chris Dyett

+44 (0) 7974 974690

ir@melroseplc.net

 

 

Melrose Industries PLC Stratton House 5 Stratton Street London W1J 8LA Tel: 020 7647 4500 Fax: 020 7647 4501

 

Registered in England & Wales Registered no: 09800044 Registered office: 11th floor The Colmore Building Colmore Circus Queensway Birmingham West Midlands B4 6AT 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDZLFBLELBBBZ
Date   Source Headline
19th Jun 20237:00 amRNSHolding(s) in Company
16th Jun 20234:45 pmRNSDirectorate Change
16th Jun 20231:30 pmRNSHolding(s) in Company
14th Jun 20236:19 pmRNSDirector/PDMR Shareholding
13th Jun 20234:50 pmRNSHolding(s) in Company
9th Jun 202310:00 amRNSHolding(s) in Company
8th Jun 20231:15 pmRNSResult of AGM
2nd Jun 202310:30 amRNSHolding(s) in Company
18th May 20235:15 pmRNSDirector/PDMR Shareholding
18th May 20234:02 pmRNSDirector/PDMR Shareholding
17th May 20231:00 pmRNSCapital Markets Event & New 2025 Guidance
15th May 20237:00 amRNSHolding(s) in Company
11th May 20235:15 pmRNSHolding(s) in Company
10th May 20237:00 amRNSTrading Update & New Guidance
5th May 20237:00 amRNSHolding(s) in Company
4th May 20237:00 amRNSHolding(s) in Company
27th Apr 202311:05 amRNSHolding(s) in Company
25th Apr 20234:35 pmRNSAnnual Report and Notice of Annual General Meeting
21st Apr 20234:00 pmRNSPost-Offer Undertakings Announcement
20th Apr 202312:20 pmRNSHolding(s) in Company
20th Apr 202311:55 amRNSDirector/PDMR Shareholding
20th Apr 20238:14 amRNSCompletion of the demerger of Dowlais
18th Apr 202311:30 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSDirector Declaration
13th Apr 20235:30 pmRNSMelrose Industries
3rd Apr 20237:00 amRNSHolding(s) in Company
31st Mar 20234:00 pmRNSConfirmation of Post-Offer Undertakings
30th Mar 202311:45 amRNSResults of General Meeting
17th Mar 20235:15 pmRNSDirector Declaration
16th Mar 20232:00 pmRNSSecond Interim Dividend - Payment Date
6th Mar 20234:15 pmRNSHolding(s) in Company
3rd Mar 20234:10 pmRNSPublication of a Prospectus
3rd Mar 20234:00 pmRNSCirc re. Demerger Proposal
2nd Mar 20237:00 amRNSFinal Results
17th Feb 20235:00 pmRNSDirector Declaration
31st Jan 20239:45 amRNSHolding(s) in Company
20th Jan 202312:30 pmRNSHolding(s) in Company
19th Jan 20237:00 amRNSTrading Update & Capital Markets Event
9th Jan 20237:00 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSCapital Markets Event
16th Nov 20223:00 pmRNSDirector/PDMR Shareholding
15th Nov 20227:00 amRNSTrading Statement
4th Nov 20225:30 pmRNSDirector Declaration
31st Oct 20227:00 amRNSHolding(s) in Company
27th Oct 20225:37 pmRNSHolding(s) in Company
26th Oct 20225:00 pmRNSDirector/PDMR Shareholding
21st Oct 20229:45 amRNSHolding(s) in Company
17th Oct 20223:00 pmRNSHolding(s) in Company
10th Oct 20227:00 amRNSHolding(s) in Company
29th Sep 20224:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.